Browsing Tag
Ohtuvayre
6 posts
Is Merck building the next great cardiometabolic franchise? A closer look at WINREVAIR, enlicitide and Ohtuvayre
See how Merck is building a cardiometabolic growth engine with WINREVAIR, enlicitide and Ohtuvayre—and what it means for investors.
What makes Ohtuvayre different from Spiriva or Trelegy? Inside the science of dual inhibition
How is Ohtuvayre different from Spiriva and Trelegy? Discover why Merck’s dual PDE3/PDE4 inhibition could change COPD treatment standards.
Will Merck’s Ohtuvayre pricing strategy face EU pushback during HTA reviews?
Will EU payers push back on Merck’s Ohtuvayre pricing? Find out how HTA reviews may shape COPD access, margins, and the drug’s long-term European rollout.
Can fixed-dose combinations make Ohtuvayre Merck’s next billion-dollar respiratory franchise?
Can a fixed-dose combo turn Ohtuvayre into Merck’s next billion-dollar COPD franchise? Find out how lifecycle strategy may reshape respiratory care.
Can Merck turn Ohtuvayre into a global COPD blockbuster? A look at pricing, access, and lifecycle strategy
Can Merck scale Ohtuvayre into a global COPD blockbuster? Explore its pricing strategy, global access plans, and lifecycle ambitions in this in-depth analysis.
Merck to acquire Verona Pharma for $10bn, securing Ohtuvayre COPD therapy
Verona Pharma stock jumps 20% as Merck announces $10B acquisition to boost its COPD pipeline with first-in-class therapy Ohtuvayre. Read full analysis.